Brief: BioInvent Reports Positive BI-1206 Clinical Data

BioInvent International AB

04/11/2021 13:11

Nov 4 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT TO SHOW FURTHER POSITIVE BI-1206 CLINICAL DATA
IN
DECEMBER AT ASH 2021
    * ANNOUNCES ADDITIONAL POSITIVE INTERIM TOP-LINE DATA FROM
ITS
NOVEL ANTI-FCΓRIIB ANTIBODY BI-1206
    * DATA UPDATE COMES FROM COMPANY'S PHASE 1/2A CLINICAL TRIAL
OF
BI-1206 IN COMBINATION WITH RITUXIMAB (ANTI-CD20 MONOCLONAL
ANTIBODY) TREATING PATIENTS WITH INDOLENT RELAPSED OR REFRACTORY
B-CELL NON-HODGKIN'S LYMPHOMA (NHL)

Source text for Eikon:  ID:nMFN9WcD97 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))